Antibiotics to treat multi-drug-resistant bacterial infections
|
|
- Lewis Lambert
- 5 years ago
- Views:
Transcription
1 Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 1
2 Forward Looking Statements and Other Important Cautions Any statements in this presentation about future expectations, plans and prospects for the Company, including statements about regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words believes, anticipates, plans, expects, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: our ability to obtain marketing approval for and commercialize eravacycline; our efforts to develop an oral formulation of eravacycline; our ability to demonstrate safety and efficacy to the satisfaction of the FDA or comparable regulatory authorities outside the United States in our clinical trials of eravacycline; our commercialization and marketing capabilities; our cash resources; and other factors discussed in the Risk Factors section of our registration statement on Form S-1. In addition, the forward-looking statements included in this presentation represent the Company s views as of July 9, The Company anticipates that subsequent events and developments will cause the Company s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company s views as of any date subsequent to July 9,
3 Deadly Multi-Drug-Resistant Gram Negative Infections Are A Growing Threat January 30, 2013 September 14, 2012 NIH superbug claims 7th Victim KPC producing bacteria have emerged as a highly drug resistant Gram-negative bacteria associated with mortality rates ranging from 32% to 48% (SENTRY surveillance program) March 5, 2013 CDC: Deadly, drug-defying CRE bacteria on rise in U.S. hospitals March 5, 2013 Deadly Bacteria That Resist Strongest Drugs Are Spreading Los Angeles County, one of the few places where Klebsiella pneumonia carbapenemase (KPC) is being tracked, detected 356 cases in the second half of
4 Tetraphase Pharmaceuticals: Overview Pipeline of differentiated antibiotics from proprietary chemistry platform focused on multi-drug resistant (MDR) Gram negative infections Lead product eravacycline in Phase 3 Potential for best in class activity in MDR Gram negative infections Broad spectrum, first line monotherapy IV and potential for oral >3.5 million patient estimated MDR market in the US Two indications for the price of one Two Phase 3 studies can support two indications Optimize reimbursement and commercial uptake $80M in proceeds from IPO, expected to be sufficient to top-line Phase 3 data In addition potential non-dilutive US Government funding of up to $100M 4
5 Complicated Intra-Abdominal Infections (ciai): New Drugs Needed to Cover Resistant Bacteria Approximately 1.7M Patients in the US (1) 38% of patients treated for ciai Treated EMPIRICALLY for suspicion of Gram Negative (2) 70% have a mixed infection involving Gram-negative and Grampositive pathogens (2) Successfully treated with 1 st line empiric therapy (2) 73% Fail 1 st line empiric therapy (2) 27% % ciai patients with confirmed infection due to specific Gram Negative pathogens (2) 7% 58% 22% 3% P. aeruginosa E. coli K. pneumoniae Acinetobacter 1. Company estimates based on various industry sources 2. Based on physician market survey 5
6 Complicated Urinary Tract Infections (cuti): New Drugs Needed to Cover Resistant Infections Approximately 4M Patients in the US (1) cuti patients treated EMPIRICALLY for suspicion of GNI (2) 78% 25% of cuti patients treated empirically with therapies that cover MDR Gram negatives (2) Successfully treated with 1 st line empiric therapy (2) 76% Fail 1 st line empiric therapy (2) 24% Increase in resistance to fluoroquinolones (25-30%) Significant market opportunity: QD I.V. (outpatient etc) or I.V./oral step down 1. Company estimates based on various industry sources 2. Based on physician market survey 6
7 History of Tetracyclines Limited Variety In Semi-synthetic Approach ( )-Chlortetracycline ( )-Doxycycline ( )-Tigecycline H H 3 C 3 C Cl N HO H H O OH O HO H O CH 3 OH NH 2 O H 3 C HO H 3C N H H O OH O HO H O CH 3 OH NH 2 O H 3 C H 3 C H N CH 3 O H 3 C CH N 3 N H H H 3 C H N O OH O HO H O CH 3 OH NH 2 O ? H H 3 C 3 C H N HO H H O OH O HO H O CH 3 OH NH 2 O H 3 C CH N 3 H H 3 C H N O OH O HO H O CH 3 OH NH 2 O H 3 C H 3 C CH 3 H N H 3 C CH N 3 H H 3 C H N O OH O HO H O CH 3 OH NH 2 O ( )-Tetracycline ( )-Minocycline PTK
8 Tetraphase Chemistry Technology Offers Novel Antibiotic Development Opportunity Eravacycline TP-834 TP-271 Pseudomonas/Gram -ve Positions that can be practically modified through conventional semi-synthesis and Tetraphase s technology Positions that can only be practically modified through Tetraphase s technology Fully synthetic chemistry that is commercially scalable Enables Strong IP and barrier to entry 8
9 Unique Synthesis of Novel Tetracyclines novel analogs 50+ novel scaffolds Eravacycline Broad Spectrum IV/Oral TP-271 Monotherapy IV/Oral TP-834 Monotherapy IV/Oral Pseudomonas / Gram -ve Leads 9
10 Tetraphase Pipeline From Internal Chemistry Platform Program Target Indications Preclinical IND Enabling Studies Phase 1 Phase 2 Phase 3 Eravacycline* Broad Spectrum IV ciai cuti Eravacycline Broad Spectrum Oral Stepdown ciai cuti TP-834 IV/Oral CABP (including MRSA and atypicals) TP-271** IV/Oral Bacterial Biothreats Pseudomonas / Gram-ve Program MDR Gram-negative * Funding from BARDA Biomedical Advanced Research and Development Authority ** Funding from NIAID National Institute of Allergy and Infectious Diseases 10
11 JUNE
12 MIC90 (µg/ml) ERAVACYCLINE Broad Spectrum Coverage of Gram-Negative Pathogens In Vitro MIC 90 Comparison Piperacillin/Tazobactam Gentamicin Ceftazidime/Cefotaxime Fluoroquinolone Carbapenem Tigecycline Eravacycline MIC - minimum inhibitory concentration Pip/Tazo and Ceftazidime/Cefotaxime truncated at 32 µg/ml 12
13 MIC90 in μg/ml ERAVACYCLINE Broad Spectrum Against Gram-Positive Pathogens In Vitro MIC 90 Comparison Levofloxacin Daptomycin Linezolid Vancomycin Tigecycline Eravacycline MIC 90 values are truncated at 8 µg/ml 13
14 MIC90 (µg/ml) ERAVACYCLINE Broad Spectrum Coverage of Anaerobes In Vitro MIC 90 Comparison Vancomycin Metronidazole Imipenem Tigecycline TP-434 Eravacycline isolates/species Vancomycin and Metronidazole MIC 90 values truncated at 16 µg/ml 14
15 ERAVACYCLINE IV Phase 2 ciai Overview Randomized, double blind study in ciai Primary endpoint: Clinical outcome in the microbiologically evaluable (ME) population at test of cure visit 143 Patients with ciai Randomized (2:2:1) Eravacycline 1.5 mg/kg IV q 24h (ME=42) Eravacycline 1.0 mg/kg IV q 12h (ME=41) Ertapenem 1.0 g IV q 24h (ME=26) 15
16 Percent Cure ERAVACYCLINE IV Demonstrated Efficacy in Phase 2 Clinical Response at Test of Cure Visit in Microbiologically Evaluable Population TP 1.5 Eravacycline TP 1.0 E Eravacyline 1.5mg/kg q24h 1.0mg/kg q12h Ertapenem 95% CI
17 ERAVACYCLINE IV Bacteria Isolated in Phase 2 25% of Gram Negative Bacteria Were Multi-Drug-Resistant Other Gram-positive spp., 0.9% Staphylococcus spp., 6.1% Anaerobes, 8.5% Enterococcus spp., 7.5% Escherichia coli, 44.3% Streptococcus spp., 9.0% GN Non-fermentors, 7.5% Other Enterobacteriaceae, 6.1% Klebsiella spp., 9.9% Average of 1.8 isolates/patient (m-mitt population) 17
18 ERAVACYCLINE IV Minimal Adverse Events Reported Adverse Events Possibly Related to Study Drug* Eravacycline 1.5mg/kg q24h N=53 Eravacycline 1.0mg/kg q12h N=56 Ertapenem N=30 Any Treatment related AE 2 (3.8%) 3 (5.4%) 3 (10.0%) Nausea - 2 (3.6%) 1 (3.3%) Vomiting 1 (1.9%) 1 (1.8%) - Elevated amylase (3.3%) Elevated lipase (3.3%) Thrombophlebitis - 1 (1.8%) - * ITT population 18
19 ERAVACYCLINE ORAL Development Plan to Define Oral Dosing Completed Phase I Oral SAD and MAD Single-center, placebo-controlled, double-blinded studies PK is linear; AUC is linear and dose-proportional Orally bioavailable 300mg QD and 100mg BID well tolerated Ongoing studies planned to be completed mid 2013 Phase 1 PK program to evaluate ascending oral doses 19
20 ERAVACYCLINE Profile of a Well-Differentiated Antibiotic FEATURE Demonstrated clinical efficacy Safe and well tolerated in patients: Minimal GI side effects Convenient dosing: Monotherapy Once daily dosage supported Broad Spectrum Antibiotic Covers gram ve, gram +ve, anaerobes and atypicals Active against difficult-to-treat MDR gram ve pathogens Potential for oral step down therapy 20
21 ERAVACYCLINE Phase 3 Ready NDA package: one pivotal study in ciai, one in cuti Plan reviewed with FDA at EOP2 meeting in January 2013 Plan follows new FDA Guidance Document ciai Guidance issued September 2012 No longer requires two pivotal studies in the same indication PHASE 3 PROGRAM ciai Non inferiority study IV q12h 3Q2013 cuti Non inferiority study Plan to switch to IV q24h/oral step down Estimated Start: 4Q
22 Resistance Increasing for Gram-negative Marketed Products (1) ZOSYN PRIMAXIN MERREM I.V. LEVAQUIN TYGACIL Pfizer; Generics Merck; Generics AZ J&J Pfizer / Wyeth Ampicillin + β- lactamase inhibitor Carbapenem Carbapenem Quinolone Tetracycline 3-4x day IV 3-4x day IV, IM 3-4x day IV 1x day PO, IV 2x day IV 1. As of June 2013 Public Information 22
23 Gram-negative Compounds In Development (1) Eravacycline Ceftolozane/ Tazobactam Ceftazidime/ Avibactam Ceftaroline/ Avibactam Tetraphase Cubist AZ AZ Phase 3 Phase 3 Phase 3 Phase 3 Tetracycline Cephalosporin + β- lactamase inhibitor Cephalosporin + β- lactamase inhibitor Cephalosporin + β- lactamase inhibitor QD/BID IV Oral 3x/ day IV 3x/day IV 3x day IV Eravacycline has convenient IV dosing with potential for oral step down 1. As of June 2013 Public Information 23
24 Strong Intellectual Property Estate Exclusive rights from Harvard to proprietary chemistry technology used to create novel fully-synthetic tetracycline analogs Patents for the process for developing novel fully synthetic tetracycline analogs Composition of matter of key intermediates used in the synthesis Composition of matter application pending on eravacycline If issued would extend through at least
25 Experienced Management Team Guy Macdonald President and Chief Executive Officer Patrick Horn, M.D., Ph.D. Chief Medical Officer Joyce Sutcliffe, Ph.D. SVP, Biology David Lubner SVP, Chief Financial Officer Xiao-Yi Xiao, Ph.D. VP, Medicinal Chemistry Magnus Ronn, Ph.D. VP, Pharmaceutical Sciences Leland Webster, Ph.D., M.B.A. VP, Business Development 25
26 Milestones Initiate Phase 3 ciai study 3Q2013 Complete Oral Phase 1 PK program Mid 2013 Data read-out 2H 2013 Initiate Phase 3 cuti study 4Q2013 Top-line readout from both Phase 3 studies 1Q
27 Tetraphase Pharmaceuticals : Summary Pipeline of differentiated antibiotics from proprietary chemistry platform focused on multi-drug resistant (MDR) Gram negative infections Lead product eravacycline in Phase 3 Potential for best in class activity in MDR Gram negative infections Broad spectrum, first line monotherapy IV and potential for oral >3.5 million patient estimated MDR market in the US Two indications for the price of one Two Phase 3 studies can support two indications Optimize reimbursement and commercial uptake $80M in proceeds from IPO, expected to be sufficient to top-line Phase 3 data In addition potential non-dilutive US Government funding of up to $100M 27
28 Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 28
TP Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals
TP-676 Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals Tetraphase Pharmaceuticals Overview Tetraphase is developing novel antibiotics for serious and life-threatening Gram-negative MDR
More informationXERAVATM (eravacycline): A Novel Fluorocycline Antibacterial
XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial Matteo Bassetti, MD, PhD Infectious Diseases Division University of Udine and Santa Maria Misericordia University Hospital Udine, Italy Disclosures
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationZoliflodacin (ETX0914) for Uncomplicated Gonorrhoea
Zoliflodacin (ETX0914) for Uncomplicated Gonorrhoea Global Antibiotic Research and Development Partnership, Pasteur Institute, 29 February, 2016 Entasis Therapeutics - Introduction Entasis Therapeutics
More informationPlazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
More informationOragenics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 25, 2018
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationBelow is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:
SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationXerava (eravacycline) NEW PRODUCT SLIDESHOW
Xerava (eravacycline) NEW PRODUCT SLIDESHOW Introduction Brand name: Xerava Generic name: Eravacycline Pharmacological class: Tetracycline antibiotic Strength and Formulation: 50mg; per vial; lyophilized
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationCHMP extension of indication variation assessment report
23 April 2015 EMA/CHMP/245949/2015 adopted Committee for Medicinal Products for Human Use (CHMP) Invented name: Tygacil International non-proprietary name: TIGECYCLINE Procedure No. EMEA/H/C/000644/II/0092
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationβ- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication
Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae
More informationPresented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
More informationOther β-lactam. A. Carbapenems:
A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationHOSPITAL EPIDEMOLOGY AND INFECTION CONTROL: STANDARD AND TRANSMISSION-BASED ISOLATION
Appendix 1: Carbapenem-Resistant Enterobacteriacaea (CRE) I. Definition: 2015 CDC definition of CRE are Enterobacteriaceae 1 that are: A. Resistant to any carbapenem antimicrobial (i.e., minimum inhibitory
More informationInfectious Disease in the Critically Ill Patient
Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationOptions for Complicated Skin and Skin Structure Infections. Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ.
Options for Complicated Skin and Skin Structure Infections Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator for,
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationChallenges of HABP/VABP Trials
Challenges of HABP/VABP Trials CTTI - 22 April, 2013 H. David Friedland, MD Cerexa Inc., a wholly owned subsidiary of Forest Laboratories Disclosures Employee of Cerexa, a wholly owned subsidiary of Forest
More informationN A S D A Q : E V F M
N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide
Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationPlazomicin for complicated urinary tract infection
October 2016 Horizon Scanning Research & Intelligence Centre Plazomicin for complicated urinary tract infection NIHR HSRIC ID: 9787 Lay summary Serious infections caused by Gram-negative bacteria are becoming
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationShaun Yang, PhD, D(ABMM), MLS(ASCP) CM MB CM Assistant Professor of Pathology UNM Health Sciences Center Associate Director of Infectious Disease
Shaun Yang, PhD, D(ABMM), MLS(ASCP) CM MB CM Assistant Professor of Pathology UNM Health Sciences Center Associate Director of Infectious Disease Director of Molecular Infectious Disease TriCore Reference
More informationNew treatments of multidrug-resistant Gram-negative ventilatorassociated
Review Article Page 1 of 22 New treatments of multidrug-resistant Gram-negative ventilatorassociated pneumonia Garyphallia Poulakou 1, Styliani Lagou 1, Drosos E. Karageorgopoulos 2, George Dimopoulos
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationAntibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:
Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Michael Satlin, MD, MS Assistant Professor of Medicine Division of Infectious Diseases Weill Cornell Medicine March 4, 2016 1 Disclosures
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationAchaogen Launches ZEMDRI (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cuti)
Achaogen Launches ZEMDRI (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cuti) -- ZEMDRI now available for ordering in the U.S. -- -- ZEMDRI demonstrated in vitro
More informationShirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate
Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Professor of Pharmacy & Associate Member of Medicine, UBC
More informationOragenics Shareholder Update
January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCommunity-acquired pneumonia (CAP)
Community-acquired pneumonia (CAP) Keith F Barker, MD GlaxoSmithKline 1 CAP: Key issues Definitions and patient population Use of prior antibiotics Microbiologically Evaluable population Efficacy endpoints
More informationAcute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016
Acute Cholangitis Kelsey Knotts PharmD Candidate Class of 2016 Learning Objectives 1. Describe the mechanism of the development of acute cholangitis 2. Identify common causative organisms in acute cholangitis
More informationLJPC-401 Phase 1 Results and Development Update. September 7, 2016
LJPC-401 Phase 1 Results and Development Update September 7, 2016 Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More informationInfections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationNew insights in antibiotic and antifungal therapy in the compromised host
New insights in antibiotic and antifungal therapy in the compromised host Claudio Viscoli University of Genova Ospedale Policlinico San Martino, Genova Potential conflicts of interest (last 5 years) Received
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationFraser Health pandemic preparedness
Fraser Health pandemic preparedness DRAFT Last revised: April 2006 General Management of Patients in Acute Care Facilities During an Influenza Pandemic 1. OVERVIEW GENERAL MANAGEMENT OF PATIENTS IN ACUTE
More informationNew Antimicrobials: Now and In the Future
New Antimicrobials: Now and In the Future David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical School Conflicts of Interest Melinta
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationRezafungin: A Novel Echinocandin. Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018
: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics. Cidara Pipeline Program
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationWhat is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden
What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationSensitivity of Surveillance Testing for Multidrug-Resistant Gram-Negative Bacteria in the
JCM Accepts, published online ahead of print on 20 August 2014 J. Clin. Microbiol. doi:10.1128/jcm.02369-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Sensitivity of Surveillance
More informationTRANSPARENCY COMMITTEE. Opinion. 07 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 07 January 2009 500 mg, powder for solution for perfusion B/10 bottles (CIP: 387 355-6) Applicant: JANSSEN-CILAG doripenem
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationLa neutropenia febbrile
XII Corso Avanzato di Terapia Antibiotica Pisa, 15-16 novembre 2017 La neutropenia febbrile Alessandra Micozzi Dipartimento di Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Fever developing
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationDrug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD
Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationDiane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center
Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal
More informationOppenheimer 29th Annual Healthcare Conference Mark Timney, Chief Executive Officer
Oppenheimer 29th Annual Healthcare Conference Mark Timney, Chief Executive Officer New York City 20th March 2019 1 Safe Harbor Forward-looking statements Statements contained in this presentation about
More informationEmergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH
Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.
More informationPaul McGovern, MD Vice President, Clinical Affairs Paratek Pharmaceuticals, Inc. Presented at ECCMID, 22 April 2018, Madrid, Spain.
A phase-3 randomized, double-blind, multicentre study to compare the safety and efficacy of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 study) Paul McGovern, MD
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationCapricor Therapeutics
Therapeutics Conference Call to Discuss the HOPE-2 Clinical Trial NASDAQ: CAPR November 29, 2017 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationAuthor: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents
t Title: In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 Author: Souha Kanj Andrew Whitelaw
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More informationHepatitis C Treatment and the Role of the Pharmacist
Infectious Diseases Odds and Ends: Focus on Developments in Hepatology and Gram-Negative Infections Lindsey Childs-Kean, PharmD, MPH, BCPS Clinical Assistant Professor University of Florida College of
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationStrategic priority to fight AMR
Strategic priority to fight AMR Launching a new program MRC meeting London 5 July 2017 Wellcome s framework for supporting science Advancing ideas We support great ideas and inspired thinking Seizing opportunities
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationTreatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
REVIEW ARTICLE Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections Haley J. Morrill, 1,2 Jason M. Pogue, 3 Keith S. Kaye, 4 and Kerry L. LaPlante 1,2,5 1 Veterans Affairs Medical Center,
More information